These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8145599)

  • 21. Cost effectiveness of combination therapy. Based on a presentation by Daniel Hilleman, PharmD.
    Am J Manag Care; 1999 Jun; 5(7 Suppl):S449-53; discussion S453-5. PubMed ID: 10538853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Antihypertensive Medication Adherence With Healthcare Use and Medicaid Expenditures for Acute Cardiovascular Events.
    Yang Z; Howard DH; Will J; Loustalot F; Ritchey M; Roy K
    Med Care; 2016 May; 54(5):504-11. PubMed ID: 27078823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacy-enforced outpatient drug treatment protocols: a case study of Medi-Cal restrictions for cefaclor.
    McCombs JS; Nichol MB
    Ann Pharmacother; 1993 Feb; 27(2):155-61. PubMed ID: 8439688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost of hypertension treatment.
    Odell TW; Gregory MC
    J Gen Intern Med; 1995 Dec; 10(12):686-8. PubMed ID: 8770721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007; 29 Spec No():1294-305. PubMed ID: 18046929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antihypertensive medication adherence and subsequent healthcare utilization and costs.
    Pittman DG; Tao Z; Chen W; Stettin GD
    Am J Manag Care; 2010 Aug; 16(8):568-76. PubMed ID: 20712390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic Health Outcomes and Prescription Drug Copayments in Medicaid.
    Kostova D; Fox J
    Med Care; 2017 May; 55(5):520-527. PubMed ID: 28234755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving cost-effectiveness of hypertension management at a community health centre.
    Edwards PR; Lunt DW; Fehrsen GS; Lombard CJ; Steyn K
    S Afr Med J; 1998 May; 88(5):549-54. PubMed ID: 9638122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimated annual direct expenditures in the United States as a result of inappropriate hypertension treatment according to national treatment guidelines.
    Balu S
    Clin Ther; 2009 Jul; 31(7):1581-94. PubMed ID: 19695408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Costs of current antihypertensive therapy in Switzerland: an economic evaluation of 3,489 patients in primary care.
    Schäfer HH; Scheunert U
    Swiss Med Wkly; 2013; 143():w13854. PubMed ID: 24163048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic implications of evidence-based prescribing for hypertension: can better care cost less?
    Fischer MA; Avorn J
    JAMA; 2004 Apr; 291(15):1850-6. PubMed ID: 15100203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension].
    Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L
    Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623
    [No Abstract]   [Full Text] [Related]  

  • 35. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
    Gilmer TP; Dolder CR; Lacro JP; Folsom DP; Lindamer L; Garcia P; Jeste DV
    Am J Psychiatry; 2004 Apr; 161(4):692-9. PubMed ID: 15056516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness issues in hypertension control.
    Schueler K
    Can J Public Health; 1994; 85 Suppl 2():S54-6. PubMed ID: 7804952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the total cost of treating elderly hypertensive patients with ACE inhibitors: a comparison of older and newer agents.
    Small RE; Freeman-Arnold SB; Goode JV; Pyles MA
    Pharmacotherapy; 1997; 17(5):1011-6. PubMed ID: 9324190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.
    Soumerai SB; McLaughlin TJ; Ross-Degnan D; Casteris CS; Bollini P
    N Engl J Med; 1994 Sep; 331(10):650-5. PubMed ID: 8052275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The (cost-)effectiveness of a patient-tailored intervention programme to enhance adherence to antihypertensive medication in community pharmacies: study protocol of a randomised controlled trial.
    van der Laan DM; Elders PJ; Boons CC; Bosmans JE; Nijpels G; Hugtenburg JG
    Trials; 2017 Jan; 18(1):29. PubMed ID: 28103948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART).
    Rothbard AB; Lee S; Blank MB
    J Ment Health Policy Econ; 2009 Dec; 12(4):187-94. PubMed ID: 20195006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.